Comparison

Cagrilintide vs. Pramlintid

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Cagrilintide

Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.

Pramlintid

Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Cagrilintide	Pramlintid
Germany	Unapproved	Unapproved
DK	Unapproved	—
United States	Unapproved	Prescription

Full entries

Frequently asked questions

What is the difference between Cagrilintide and Pramlintid?: Cagrilintide is classified as "Metabolic", while Pramlintid is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cagrilintide or Pramlintid?: The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cagrilintide and Pramlintid in Germany and the United States?: Germany: Cagrilintide — Unapproved, Pramlintid — Unapproved. United States: Cagrilintide — Unapproved, Pramlintid — Prescription. These are factual summaries with source and review date on the individual pages.

Country

Cagrilintide

Pramlintid

Germany

Unapproved

—

United States

Unapproved

Prescription

Frequently asked questions

What is the difference between Cagrilintide and Pramlintid?

Cagrilintide is classified as "Metabolic", while Pramlintid is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cagrilintide or Pramlintid?

The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cagrilintide and Pramlintid in Germany and the United States?

Germany: Cagrilintide — Unapproved, Pramlintid — Unapproved. United States: Cagrilintide — Unapproved, Pramlintid — Prescription. These are factual summaries with source and review date on the individual pages.